Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer
Metadatos
Mostrar el registro completo del ítemAutor
Pedraz Valdunciel, Carlos; Giannoukakos, Stavros Panagiotis; Fernández Hilario, Alberto Luis; Hackenberg, MichaelEditorial
MDPI
Materia
circRNAs Extracellular vesicles nCounter Lung cancer NSCLC Liquid biopsies
Fecha
2022-09-24Referencia bibliográfica
Pedraz-Valdunciel, C... [et al.]. Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer. Pharmaceutics 2022, 14, 2034. [https://doi.org/10.3390/pharmaceutics14102034]
Patrocinador
European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant 765492Resumen
Background: The analysis of liquid biopsies brings new opportunities in the precision
oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained
interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols
need to be developed to boost their potential in the clinical setting. Although nCounter has been
used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed
for EV-circRNA analysis of LC patients. Methods: EVs were isolated from early-stage LC patients
(n = 36) and controls (n = 30). Different volumes of plasma, together with different number of preamplification
cycles, were tested to reach the best nCounter outcome. Differential expression analysis
of circRNAs was performed, along with the testing of different machine learning (ML) methods for
the development of a prognostic signature for LC. Results: A combination of 500 L of plasma input
with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found
upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from
controls with AUC ROC of 0.86. Conclusions: This study validates the use of the nCounter platform
for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of
prognostic signatures.